Swiss Re cancer outlook reshapes risk view for Swiss Re stock

Published on 10/29/2026 at 10:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Swiss Re projects cancer mortality falling 19-38 percent in the US by 2044. Swiss Re stock costs EUR 164.45 on October 29, 2026.

Cancer risk meets insurance design

Swiss Re published its cancer outlook on October 22, 2026, projecting a 19-38 percent decline in US mortality by 2044.
About 4 in 10 people in the US and UK are projected to develop cancer during their lifetime.
Swiss Re stock traded at EUR 164.45 at 10:35 a.m. CET at Lang & Schwarz on October 29, 2026.

Swiss Re, CH0126881561, Illustration mit AI erstellt.

Swiss Re's cancer outlook adds a new risk lens for insurers as Swiss Re stock traded at EUR 164.45 at Lang & Schwarz on October 29, 2026, at 10:35 a.m. CET. In research published on October 22, 2026, Swiss Re projected falling cancer mortality but warned that longer survival and population aging could create new insurance demands.

Mortality falls while diagnoses diverge

Swiss Re analyzed breast, colorectal, lung, pancreatic and prostate cancer in the US and UK. Together, the five cancers account for about half of cancer diagnoses and deaths in the general population, according to the study.

For the US, the combined age-standardized mortality rate is projected to decline by 19 percent to 38 percent by 2044. The comparable UK projection is a 14 percent to 36 percent decline by 2043, although Swiss Re cautioned that the country results use different standard populations.

What changes for insurance?

The research points to different effects across product lines. Falling mortality could reduce or delay life-insurance claims, while more diagnoses and earlier detection could increase or bring forward critical-illness claims. Longer survival can also extend exposure to recurrence, disability and long-term care needs.

Swiss Re said about 4 in 10 people in the US and UK will develop cancer during their lifetime. It also estimated that 44 percent of cancer deaths globally are attributable to modifiable risk factors, linking underwriting questions to changing health behavior and medical progress.

Next results date

Swiss Re's next scheduled reporting event is its Nine Months 2026 Results media conference on November 5, 2026, at 8:30 a.m. CET, according to the company's event page. The cancer study does not provide a forecast for Swiss Re's earnings; its investor relevance lies in how insurers may price, reserve and design products as survival patterns change.

Stock trades at EUR 164.45

Swiss Re stock was trading at EUR 164.45 at Lang & Schwarz on October 29, 2026 at 10:35 a.m. CET. The further course of trading is shown by the continuously updated real-time quote of Swiss Re stock.